← Back to Clinical Trials
Recruiting NCT06556667

MAX - SHOCK Clinical Trial

Trial Parameters

Condition Cardioversion
Sponsor Ottawa Heart Institute Research Corporation
Study Type INTERVENTIONAL
Phase N/A
Enrollment 376
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-03-31
Completion 2027-09-01
Interventions
biphasic defibrillator with maximum energy of 200J (® Zoll)biphasic defibrillator with maximum energy of 360J (® Physio-Control)

Brief Summary

Can Electrical Cardioversion (ECV) for AF be improved. It is the preferred method to restore sinus rhythm in patients with AF in whom a rhythm-control strategy is pursued. Hypothesis: ECV success rates will be greater with a biphasic defibrillator with maximum energy of 360J (® Physio-Control) compared to a biphasic defibrillator with maximum energy of 200J (® Zoll)

Eligibility Criteria

Inclusion Criteria: * Patients age \> 18 years. * Persistent atrial fibrillation. * Scheduled for elective cardioversion at UOHI * Patient is within the circle of care of UOHI Electrophysiology staff Exclusion Criteria: * Known left-atrial appendage thrombus. * Contraindication to appropriate anticoagulation. * Patient is included in another randomized clinical trial. * Patient does not meet all of the above listed inclusion criteria.

Related Trials